

## Health Care Market Oversight

### InformDx and Bako Pathology

The [Health Care Market Oversight](#) (HCMO) program reviews health care business deals to make sure they support Oregon’s goals of health equity, lower costs, increased access, and better care. On February 13, 2026, the Oregon Health Authority (OHA) accepted a complete Notice of Material Change Transaction (“notice”) describing plans for Inform Diagnostics, Inc. (“InformDx”) to acquire certain businesses and assets of Bako Pathology Holdings Corp. and its subsidiaries (“Bako”).

#### Who’s involved?

**InformDx** is a pathology laboratory headquartered in Texas that serves clients in most states, including approximately 21 clients in Oregon. InformDx specializes in gastrointestinal, dermatopathology, hematopathology, breast, urologic, and molecular diagnostics. The company is a wholly owned subsidiary of Fulgent Genetics, Inc., a publicly traded company.

**Bako** is a private equity owned laboratory group that provides dermatopathology, podiatric pathology, and other clinical laboratory services nationwide. Bako subsidiaries include Bako Diagnostics (“BakoDx”) based in Atlanta, GA, and Strata Pathology Services Inc. (“StrataDx”) located in Lexington, MA. Bako processes approximately 5,000 samples from Oregon patients annually.

#### About the deal

Under the proposed transaction terms, InformDx will acquire Dermatopathology Experts LLC (including StrataDx) for \$12.5 million and the assets of BakoDx for \$43 million. The entities stated there will be no changes to level of services, staffing, or payer contracts. InformDx is pursuing this deal to expand its laboratory service offerings and provide patients with broader network of pathologists.

#### What’s next?

OHA is reviewing this deal to understand how it could affect health care services for communities in Oregon. During the review, OHA will use health care data, news and media reports, information from the entities, and public input to decide whether the deal should be approved. After completing the review, OHA will issue a decision about whether the deal may proceed as planned.

#### We want to hear from you!

Public input helps OHA understand how this deal could help or harm people in your community. To share your thoughts about this deal, please email [hcmo.info@oha.oregon.gov](mailto:hcmo.info@oha.oregon.gov), leave a voicemail at 503-945-6161, or [fill out the public comment form](#). In your comment, mention “InformDx”, what you think, and whether you support or oppose the deal.

You can get this document in other languages, large print, braille, or a format you prefer free of charge. Contact us by email at [hcmo.info@oha.oregon.gov](mailto:hcmo.info@oha.oregon.gov) or by phone at 503-945-6161. We accept all relay calls.